Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
20
Recruiting, any sponsor type, condition "hypogonadism"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed235
20 trials
Showing 1 to 20, recently updated first.
University of MiamiAcademic, hospital or other
NCT07278362 · 35 participants (planned) · Start Nov 30, 2026 · Primary completion May 31, 2031
Drug: Testosterone cypionate · For: Prostate Cancer; Hypogonadism, Male
Sites: Miami, Florida · 2 sites in all
- Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With HypogonadismPivotal-lookingRecruiting
Amneal Pharmaceuticals, LLCIndustry
NCT07898072 · 190 participants (planned) · Start Sep 28, 2026 · Primary completion Mar 31, 2027
Drug: Testosterone Cypionate 75 mg; Testosterone cypionate 50 mg and 1 more · For: Male Hypogonadism
Sites: Santa Monica, California; DeLand, Florida; Miami Lakes, Florida · 10 sites in all
University Health Network, TorontoAcademic, hospital or other
NCT07535905 · 96 participants (planned) · Start Dec 31, 2026 · Primary completion Oct 2030
Drug: Tamoxifen · For: Hypogonadism; Prostate Cancer
Sites: Toronto, Canada
- Adaptions and Resiliency to Multi-Stressor OpeRationsPivotal-lookingRecruiting
Bradley NindlAcademic, hospital or other
NCT06455969 · 120 participants (planned) · Start Jul 15, 2024 · Primary completion Aug 2027
Drug: Goserelin 3.6 MG; Testosterone gel (AndroGel 5g) and 1 more · For: Musculoskeletal Injury; Hypogonadism; Hormonal Contraception
Sites: Pittsburgh, Pennsylvania
- Pain Alleviation With Testosterone in Opioid-Induced HypogonadismPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT04798469 · 150 participants (planned) · Start Jan 10, 2022 · Primary completion Sep 30, 2027
Drug: Testosterone Undecanoate 250 MG/ML; Placebo · For: Opioid Use; Pain; Hypogonadism, Male
Sites: Boston, Massachusetts
Stephanie B. Seminara, MDAcademic, hospital or other
NCT05896293 · 36 participants (planned) · Start Feb 3, 2023 · Primary completion May 2028
Drug: kisspeptin 112-121; leuprolide acetate · For: Hypogonadotropic Hypogonadism
Sites: Boston, Massachusetts
Stephanie B. Seminara, MDAcademic, hospital or other
NCT07224438 · 20 participants (planned) · Start Dec 9, 2025 · Primary completion May 2030
Drug: kisspeptin 112-121 · For: Hypothalamic Amenorrhea; Hypogonadotropic Hypogonadism
Sites: Boston, Massachusetts
- Testosterone Replacement in Male Cancer Survivors With Fatigue and Low TestosteronePivotal-lookingRecruiting
Seattle Institute for Biomedical and Clinical ResearchAcademic, hospital or other
NCT04049331 · 240 participants (planned) · Start Mar 22, 2021 · Primary completion Jan 30, 2027
Drug: Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED] · For: Hypogonadism, Male; Fatigue Syndrome, Chronic
Sites: Boston, Massachusetts; Seattle, Washington
- Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter SyndromePivotal-lookingRecruiting
Georgios PapadakisAcademic, hospital or other
NCT05586802 · 150 participants (planned) · Start Mar 21, 2023 · Primary completion Apr 30, 2027
Drug: Anastrozole; Semaglutide and 2 more · For: Klinefelter Syndrome
Sites: Lausanne, Switzerland
St. Louis UniversityAcademic, hospital or other
NCT05249634 · 20 participants (planned) · Start Mar 15, 2022 · Primary completion Jun 2028
Drug: Jatenzo Pill · For: Hypogonadism, Male; Kidney Disease, Chronic
Sites: St Louis, Missouri
- A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)Pivotal-lookingRecruiting
Rhythm Pharmaceuticals, Inc.Industry
NCT06760546 · 39 participants (planned) · Start Sep 23, 2025 · Primary completion Mar 13, 2027
Drug: Setmelanotide; Placebo · For: Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia and 3 more
Sites: Birmingham, Alabama; Aurora, Colorado; Chicago, Illinois · 11 sites in all
University of California, IrvineAcademic, hospital or other
NCT06720597 · 120 participants (planned) · Start Aug 13, 2025 · Primary completion Jan 2027
Drug: Daily low-dose PDE5 inhibitor therapy; Testosterone therapy as per clinical guidelines. · For: Erectile Dysfunction; Hypogonadism, Male; Endothelial Dysfunction
Sites: Newport Beach, California
- Tirzepatide in PWS, HO and GNSORecruiting
Grace KimAcademic, hospital or other
NCT06901245 · 36 participants (planned) · Start May 1, 2025 · Primary completion Jun 2026
Drug: Tirzepatide · For: Prader-Willi Syndrome; Hypothalamic Obesity; Obesity/Therapy
Sites: Saint Paul, Minnesota; Nashville, Tennessee; Seattle, Washington
Walter Reed National Military Medical CenterFederal agency
NCT06247267 · 75 participants (planned) · Start Mar 9, 2021 · Primary completion Aug 2025
Drug: Fortesta; Estradiol and 1 more · For: Hypogonadism; Gender Identity Dysphoria
Sites: Bethesda, Maryland
- Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord InjuryRecruiting
North Florida Foundation for Research and EducationAcademic, hospital or other
NCT04460872 · 21 participants (planned) · Start Jan 31, 2021 · Primary completion Jan 30, 2026
Drug: Testosterone Enanthate · For: Spinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System and 17 more
Sites: Gainesville, Florida; Jacksonville, Florida
- Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomyPivotal-lookingRecruiting
Canisius-Wilhelmina HospitalAcademic, hospital or other
NCT04833426 · 140 participants (planned) · Start Dec 12, 2022 · Primary completion Dec 2027
Drug: Testosterone gel; Placebo · For: Prostatic Neoplasms; Hypogonadism; Testosterone Deficiency
Sites: Amsterdam, Netherlands; Arnhem, Netherlands; Eindhoven, Netherlands · 10 sites in all
Lise AksglædeAcademic, hospital or other
NCT06294990 · 32 participants (planned) · Start Aug 15, 2024 · Primary completion Dec 31, 2029
Drug: Testosterone gel · For: Klinefelter Syndrome
Sites: Copenhagen, Denmark
- Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner SyndromeRecruiting
Aarhus University HospitalAcademic, hospital or other
NCT06570460 · 50 participants (planned) · Start Nov 29, 2021 · Primary completion Dec 31, 2026
Drug: 17-beta estradiol; 17-beta estradiol · For: Turner Syndrome; Hypogonadism; Ovarian; Hormone Replacement Therapy and 2 more
Sites: Aarhus, Denmark
Aarhus University HospitalAcademic, hospital or other
NCT06544473 · 50 participants (planned) · Start Nov 29, 2021 · Primary completion Dec 31, 2026
Drug: 17-beta estradiol; 17-beta estradiol · For: Turner Syndrome; Hypogonadism; Ovarian; Hormone Replacement Therapy and 2 more
Sites: Aarhus, Denmark
Alexandra Kautzky-WillerAcademic, hospital or other
NCT03851627 · 32 participants (planned) · Start Jan 25, 2022 · Primary completion Sep 2028
Drug: Testosterone Undecanoate; Placebo · For: Fatty Liver; Overweight/Obesity; Prediabetes/Type2 Diabetes Mellitus and 1 more
Sites: Vienna, Austria
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.